美敦力宣布有意收购SPR Therapeutics公司，为慢性疼痛患者扩展治疗选择-动脉网

Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain

CISION 等信源发布 2026-05-20 21:15



可切换为仅中文







Acquisition will enhance Medtronic's Neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) technology, enabling earlier intervention for chronic pain sufferers

收购将通过临时周围神经刺激（PNS）技术增强美敦力的神经调节产品组合，使慢性疼痛患者能够更早得到干预。

GALWAY, Ireland

爱尔兰戈尔韦

，

May 20, 2026

2026年5月20日

/PRNewswire/ -- Medtronic plc (NYSE:

/PRNewswire/ -- 美敦力公司（纽约证券交易所代码：

MDT

), a global healthcare technology leader, today announced its intent to acquire SPR Therapeutics, Inc. (SPR), a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for chronic pain management. The transaction consists of an upfront cash payment of approximately $650 million for all the outstanding equity in SPR.

），一家全球医疗技术领导者，今天宣布了其收购SPR Therapeutics, Inc.（SPR）的意向。SPR是一家私营的医疗技术公司，也是公认的在慢性疼痛管理方面领先的临时性经皮周围神经刺激（PNS）疗法提供商。此次交易包括约6.5亿美元的现金预付款，用于收购SPR的所有已发行股权。

The acquisition continues Medtronic's momentum in driving strategic deals that further build out the company's core franchises..

此次收购继续推动了美敦力在达成进一步构建公司核心业务的战略交易方面的势头。

Drawing on Medtronic's 50 years of neuromodulation leadership, including the industry's broadest pain therapy portfolio

依托美敦力在神经调节领域50年的领导地位，包括行业内最广泛的疼痛治疗产品组合

, this planned acquisition will increase Medtronic's ability to reach and support more people with complementary, minimally invasive pain relief options earlier in their care continuum.

，此次计划中的收购将增强美敦力在患者护理过程的更早阶段通过互补的微创镇痛方案接触并帮助更多人的能力。

Chronic pain affects nearly 50 million U.S. adults

慢性疼痛影响了近5000万美国成年人

, often limiting daily life and work. SPR's FDA-cleared SPRINT® PNS System is a short-term, 60-day therapy designed to provide pain relief through a temporary treatment approach that does not require a permanent implant. The therapy integrates into existing clinical workflows and enables physicians to intervene earlier, expanding patient access..

，常常限制日常生活和工作。SPR 获得 FDA 认证的 SPRINT® PNS 系统是一种短期的、为期 60 天的治疗方案，旨在通过一种无需永久植入的临时治疗方法来缓解疼痛。该疗法融入现有的临床工作流程，使医生能够及早介入，扩大患者获得治疗的机会。

'Our purpose first and foremost is to serve patients,' said Domenico De Paolis, Interim President Neuromodulation, part of the Medtronic Neuroscience Portfolio. 'That is why we continue to thoughtfully expand our pain intervention therapies. The addition of temporary peripheral nerve stimulation helps broaden access to neuromodulation and supports patients across more stages of the chronic pain journey with a minimally invasive therapy.'.

“我们的首要任务是服务患者，”美敦力神经科学业务组合中神经调节部门的临时总裁多梅尼科·德保罗利斯表示。“这就是为什么我们不断审慎地扩展我们的疼痛干预疗法。增加临时性外周神经刺激有助于拓宽神经调节的可及性，并通过一种微创疗法在慢性疼痛旅程的更多阶段为患者提供支持。”

The PNS segment continues to grow, driven by increasing clinical evidence, expanding reimbursement, and demand for non-opioid, less-invasive pain therapies. To date, the largest retrospective review of real-world PNS data, which includes more than 6,100 patients, was conducted using the SPRINT PNS System and showed over 71 percent of study participants demonstrated significant pain relief and/or improvement in quality of life following 60-day percutaneous PNS treatment.

周围神经系统（PNS）领域持续增长，得益于不断增加的临床证据、扩展的报销范围以及对非阿片类、微创疼痛治疗的需求。迄今为止，规模最大的真实世界PNS数据回顾性研究已使用SPRINT PNS系统完成，涵盖了超过6100名患者。研究表明，在接受为期60天的经皮PNS治疗后，超过71%的研究参与者显示出显著的疼痛缓解和/或生活质量改善。

。

'Guided by our credo to advancing meaningful, patient-centered innovation in pain medicine, our agreement with Medtronic marks a pivotal step forward,' said Maria E. Bennett, President and Chief Executive Officer of SPR Therapeutics. 'Together, we will reach more patients helping them find relief earlier in their care journey to reclaim their lives and get back to what matters most.'.

“以我们在疼痛医学领域推进有意义的、以患者为中心的创新为信念，我们与美敦力达成的协议标志着一个关键的前进步伐，”SPR Therapeutics总裁兼首席执行官玛丽亚·E.贝内特表示。“通过合作，我们将帮助更多患者在治疗旅程中更早找到缓解，重拾生活，回归最重要的事情。”

This transaction is subject to customary closing conditions and regulatory approvals. The anticipated close date will fall within the first half of Medtronic's Fiscal Year 2027, which officially began on April 25, 2026. Until closing, Medtronic and SPR Therapeutics will continue to operate as separate and independent companies..

本次交易需满足惯例的交割条件并获得监管批准。预计交割日期将落在美敦力2027财年上半年，该财年已于2026年4月25日正式开始。在交割完成之前，美敦力和SPR Therapeutics将继续作为独立的公司分别运营。

About Medtronic

美敦力公司简介

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更大胆的行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，通过寻找并发现解决方案，勇敢地应对人类面临的最严峻的健康问题。我们的使命——减轻病痛、恢复健康、延长生命——将遍布150多个国家的95,000多名充满热情的员工团结在一起。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们多样化的知识、无尽的好奇心和帮助所有需要帮助的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

期待我们带来更多成果，因为我们致力于推动以洞察力为基础的护理、以人为本的体验，以及为世界创造更好的结果。在我们所做的一切中，我们正在创造非凡的工程。如需更多关于美敦力的信息，请访问。

medtronic.com

美敦力官网

and follow us on

关注我们

领英

。

About SPR

关于SPR

SPR is a medical technology company focused on advancing minimally invasive therapies for the treatment of pain. Its SPRINT® PNS System is designed to deliver short-term peripheral nerve stimulation therapy for sustained pain relief, supported by a growing body of clinical evidence and expanding reimbursement coverage.

SPR是一家专注于推进微创治疗技术以治疗疼痛的医疗技术公司。其SPRINT® PNS系统旨在提供短期的外周神经刺激疗法以实现持续的疼痛缓解，并得到了越来越多的临床证据支持以及不断扩大的报销覆盖范围。

For more information on SPR Therapeutics, visit .

有关SPR Therapeutics的更多信息，请访问。

sprpainrelief.com

西班牙语疼痛缓解.com

and follow SPR on

并关注SPR的

领英

。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述均受风险和不确定性的影响，例如美敦力向美国证券交易委员会提交的定期报告中描述的那些。实际结果可能与预期结果有重大差异。

Medtronic Contacts:

美敦力联系人：

Justin Paquette

贾斯汀·帕奎特

Ingrid Goldberg

英格丽德·戈德堡

Public Relations

公共关系

Investor Relations

投资者关系

+1-612-271-7935